What is multiomics and why is it important for ageing research?

Multiomics combines genomics, transcriptomics, proteomics, metabolomics and epigenomic data. It is important for ageing research because ageing involves many interacting pathways, and measuring several layers at once gives a fuller picture than any single assay.

How does microscopy fit into multiomics ageing studies?

Microscopy adds spatial and single-cell context. It can show where senescent cells accumulate, how mitochondria change with age, or how tissues respond to an intervention, complementing the molecular data from omics platforms.

Which microscopy platforms are used for spatial multiomics?

High-resolution fluorescence microscopes, confocal systems, slide scanners and high-content screening platforms are commonly used. EVOS S1000 and CellInsight CX7 are examples of platforms that can capture multiplexed fluorescence images for spatial biology workflows.

Can multiomics microscopy speed up anti-ageing drug discovery?

Yes. By linking molecular changes to visible cellular phenotypes, researchers can prioritise compounds that affect real ageing biology rather than just shifting one biomarker. This can reduce false leads early in development.

What are the limitations of multiomics in ageing research?

Multiomics generates huge datasets that require careful statistics and validation. A molecular change does not always mean a health benefit. Findings must still be confirmed in larger cohorts and, ultimately, in clinical trials.

Multiomics Microscopy and Anti-Ageing Research: UK Lab Guide 2026

TL;DR: Ageing is too complex to understand with one experiment. Multiomics measures DNA, RNA, proteins and metabolites together, while microscopy adds the missing spatial layer — where in a tissue cells age, become senescent, or respond to a compound. Together they are reshaping how UK labs identify and validate anti-ageing interventions.

What is multiomics?

Multiomics is the simultaneous measurement of multiple biological layers. In ageing research the most relevant are:

Genomics: DNA sequence and structural variation.
Transcriptomics: which genes are turned on or off.
Proteomics: the proteins actually present in cells.
Metabolomics: small molecules such as lipids, sugars and amino acids.
Epigenomics: chemical marks on DNA that change with age and environment.

By combining these layers, researchers can move beyond single-biomarker headlines and see how pathways interact. For example, a supplement might raise NAD+ in blood but fail to restore mitochondrial function in muscle unless it also reaches the right tissue at the right dose.

Why microscopy is essential for multiomics ageing studies

Omics tells you what is changing at the molecular level; microscopy tells you where. Ageing is highly heterogeneous: not every cell in an aged tissue is senescent, and not every mitochondrion is damaged. Imaging resolves that heterogeneity by capturing:

Spatial location of senescent cells and SASP markers.
Mitochondrial morphology, number and dynamics.
Immune cell infiltration and inflammation patterns.
Tissue architecture changes, such as fibrosis or atrophy.
Single-cell phenotypes linked to multiomic profiles.

Without microscopy, multiomics can miss which cells are driving the signal. With it, researchers can validate whether a molecular change translates into a visible, functional cellular outcome.

How this is revolutionising anti-ageing discoveries

The integration of multiomics and microscopy is accelerating anti-ageing research in three ways:

Target discovery: combining epigenetic clocks with imaging reveals which tissues age fastest and why.
Compound screening: high-content imaging plus transcriptomics can quickly identify senolytics, mitophagy activators and mTOR modulators.
Mechanism validation: if a supplement changes a metabolite level, imaging can confirm whether it also reverses mitochondrial dysfunction or reduces senescence in the target tissue.

EVOS and CellInsight CX7 in UK multiomics-ageing workflows

Several microscopy platforms are useful for multiomics-ageing work in UK labs:

EVOS S1000: high-resolution fluorescence for multiplexed spatial imaging of aged tissues. Read our EVOS S1000 review.
EVOS M7000: automated live-cell imaging for time-course assays such as mitochondrial dynamics or senescence markers. Read our EVOS M7000 guide.
CellInsight CX7: high-content screening for large-scale compound and genetic screens combined with omics readouts. Read our CellInsight CX7 review.

For readers interested in the supplement side of this research, our partner site LongevityTortoise has published a companion guide: New research supplements for anti-ageing 2026: a UK roundup.

What this means for UK labs

Multiomics microscopy is not a single product; it is a workflow. UK labs that adopt it can generate richer datasets, reduce false-positive leads, and publish more robust ageing research. The key is to design experiments where imaging and omics validate each other rather than running them in isolation.